A clinical trial (NCT00494234) for a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, olaparib, in patients with BRCA1 or BRCA2 mutations and advanced breast cancer, provided an impressive ORR of 44% [45]. This evidence concerns the gene BRCA2 and breast carcinoma.